Vor Biopharma Inc.
For the period ended Dec 31, 2024. Filed Mar 20, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 20, 2025
VOR$19.56-2.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
| Year EndedDecember 31, | ||
|---|---|---|
| (in thousands, except share and per share amounts) | 2024 | 2023 |
| Operating expenses: | ||
| Research and development | $93,310 | $94,315 |
| General and administrative | 27,875 | 31,721 |
| Total operating expenses | $121,185 | $126,036 |
| Loss from operations | $(121,185) | $(126,036) |
| Other income: | ||
| Interest income | 4,271 | 8,173 |
| Total other income | 4,271 | 8,173 |
| Net loss | $(116,914) | $(117,863) |
| Net loss per share, basic and diluted | $(1.70) | $(1.75) |
| Weighted-average common shares outstanding, basic and diluted | 68,705,639 | 67,191,973 |
| Other comprehensive income: | ||
| Unrealized gain on available for sale marketable securities | 99 | 693 |
| Total other comprehensive income | 99 | 693 |
| Comprehensive loss | $(116,815) | $(117,170) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.